ArticleAnnals of clinical microbiology and antimicrobials2023
Molecular detection of plasmid mediated bla
Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Phenotypic and genotypic assessment of antimicrobial and biocide resistance in enterobacteria from anaerobic digestion of dairy waste: implications for environmental and public health.World journal of microbiology & biotechnology · 2026Article
- Co-occurrence of triple ESBL-associated genes (blaBMC infectious diseases · 2026Article
- Molecular detection of extended-spectrum β-Lactamase genes in multi-drug-resistant bacteria isolated from drinking water supply and surface water systems in Addis Ababa, Ethiopia.BMC microbiology · 2026Article
- Review
- Implementing the CRISPR 2.1 array for genotyping enhances identification of uropathogenic Escherichia coli in Colombian pediatric patients.Biomedica : revista del Instituto Nacional de Salud · 2026Article
- Resistance gene profiling of beta-lactamase and carbapenemase in gram-negative blood isolates: A tertiary care hospital.PloS one · 2026Article
- Impact of pathophysiologically relevant underlying disease burden on pathogen distribution and antimicrobial resistance in patients with device-associated urinary tract infections.Frontiers in cellular and infection microbiology · 2026Article
- Identification, resistance mechanisms, and innovative therapeutic approaches againstFrontiers in microbiology · 2026Review
- Prospective Molecular and Phenotypic Characterization ofInfection and drug resistance · 2026Article
- Article
- Molecular characterization of extended-spectrum beta-lactamase-producing bacteria isolated from pregnant women's urine at Itojo Hospital, South Western Uganda.Access microbiology · 2026Article
- Distribution and antibiotic resistance analysis of clinically isolated bacteria at a national regional cardiovascular medical center, 2018-2024.BMC infectious diseases · 2025Article
- Integrating computational approaches to uncover β-lactamase-associated resistance in diarrheagenic Escherichia coli from pediatric patients.Scientific reports · 2025Article
- Genetic characteristics and risk factors of extended-spectrum β-lactamase-producingMicrobiology spectrum · 2025Observational
- Phenotypic and Genotypic Characterization of ESBL andAntibiotics (Basel, Switzerland) · 2025Article
- Rapid whole genome sequencing for AMR surveillance in low- and middle-income countries: Oxford Nanopore Technology reveals multidrug-resistant Enterobacter cloacae complex from dairy farms in Sri Lanka.BMC veterinary research · 2025Article
- Distribution of extended-spectrum β-lactamase producingVeterinary world · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtended spectrum β-lactamases (ESBLs) are a group of beta-lactamase enzymes that confer resistance to the oxyimino-cephalosporins and monobactams. The emergence of ESBL - producing genes possesses a serious threat for treating infections since it is associated with multi-drug resistance. This study was focused to identify the ESBLs producing genes from Escherichia coli isolates from clinical samples from a referral-level tertiary care hospital in Lalitpur.
methodsThis was a cross-sectional study conducted from September 2018 to April 2020 at the Microbiology Laboratory of Nepal Mediciti Hospital. Clinical samples were processed, and culture isolates were identified and characterized following standard microbiological techniques. An antibiotic susceptibility test was performed by a modified Kirby-Bauer disc diffusion method as recommended by Clinical and Laboratory Standard Institute guidelines.Extended -spectrum beta-lactamases were phenotypically confirmed by the combined disc method. The ESBL-producing genes bla
resultsOf the 1449 total E. coli isolates, 22.29% (323/1449) isolates were multi-drug resistant (MDR). Among the total MDR E. coli isolates, 66.56% (215/323) were ESBL producers. The maximum number of ESBL E. coli was isolated from urine 90.23% (194) followed by sputum 5.58% (12), swab 2.32% (5), pus 0.93% (2), and blood 0.93% (2). The antibiotic susceptibility pattern of ESBL E. coli producers showed the highest sensitivity toward tigecycline (100%) followed by polymyxin b, colistin and meropenem. Out of 215 phenotypically confirmed ESBL E. coli, only 86.51% (186) isolates were found to be positive by PCR for either bla
conclusionThe emergence of MDR and ESBL - producing E. coli isolates with high antibiotic - resistant rates to commonly used antibiotics and increased predominance of major gene types bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.